Spots Global Cancer Trial Database for localized unresectable adult primary liver cancer
Every month we try and update this database with for localized unresectable adult primary liver cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer | NCT00274885 | Cancer | oxaliplatin management of t... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer | NCT00870558 | Liver Cancer | ethiodized oil iodine I 131 et... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery | NCT00949182 | Liver Cancer | sorafenib tosyl... laboratory biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00041275 | Liver Cancer | megestrol aceta... | 20 Years - | National Cancer Institute (NCI) | |
| T900607 in Treating Patients With Unresectable Liver Cancer | NCT00054262 | Liver Cancer | T900607 | 18 Years - | National Cancer Institute (NCI) | |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | NCT00023946 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Extra... Localized Gallb... Localized Resec... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | ixabepilone laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | NCT00077142 | Liver Cancer | TAC-101 | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | NCT00006006 | Liver Cancer | recombinant int... thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | NCT00107536 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery | NCT00873002 | Liver Cancer | panobinostat sorafenib tosyl... | 18 Years - | Case Comprehensive Cancer Center | |
| Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | NCT00073905 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pain | capecitabine pl... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00777894 | Liver Cancer | 3-dimensional c... intensity-modul... stereotactic bo... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Chemotherapy in Treating Patients With Liver Cancer | NCT00003044 | Liver Cancer | cisplatin-e the... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer | NCT00009893 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | fluorouracil gemcitabine hyd... leucovorin calc... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery | NCT00039078 | Liver Cancer | yttrium Y 90 gl... | 18 Years - 120 Years | University of Pittsburgh | |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT02072356 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | yttrium Y 90 gl... laboratory biom... TheraSphere | 8 Years - | Ohio State University Comprehensive Cancer Center | |
| Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | NCT00085410 | Adenocarcinoma ... Adenocarcinoma ... Advanced Adult ... Gastrointestina... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | NCT01229111 | Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Unres... Periampullary A... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | cediranib malea... oxaliplatin leucovorin calc... fluorouracil | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | NCT01643499 | Acinar Cell Ade... Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Diffuse Adenoca... Duct Cell Adeno... Intestinal Aden... Localized Unres... Metastatic Carc... Metastatic Extr... Mixed Adenocarc... Mucinous Adenoc... Mucinous Adenoc... Newly Diagnosed... Signet Ring Ade... Signet Ring Ade... Stage III Pancr... Stage IIIA Colo... Stage IIIA Gall... Stage IIIA Gast... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Gall... Stage IIIB Gast... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Rect... Stage IV Gastri... Stage IV Pancre... Stage IVA Colon... Stage IVA Gallb... Stage IVA Recta... Stage IVB Colon... Stage IVB Gallb... Stage IVB Recta... Unresectable Ex... | oxaliplatin irinotecan hydr... leucovorin calc... fluorouracil laboratory biom... | 18 Years - | University of Chicago | |
| Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | NCT00093444 | Liver Cancer Metastatic Canc... | lyso-thermosens... radiofrequency ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00604721 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | selumetinib pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant | NCT01194206 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | stereotactic bo... | 18 Years - 70 Years | Case Comprehensive Cancer Center | |
| Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00530010 | Liver Cancer | yttrium Y 90 gl... | 18 Years - | Northwestern University | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer | NCT00253708 | Cancer | management of t... massage therapy pain therapy psychosocial as... quality-of-life... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| T900607 in Treating Patients With Unresectable Liver Cancer | NCT00054262 | Liver Cancer | T900607 | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan and Capecitabine in Treating Patients With Solid Tumors | NCT00003867 | Cancer | capecitabine irinotecan hydr... | 18 Years - 120 Years | Montefiore Medical Center | |
| Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | NCT00002608 | Adrenocortical ... Brain and Centr... Head and Neck C... Liver Cancer Malignant Mesot... Pheochromocytom... Sarcoma | cisplatin doxorubicin hyd... tamoxifen citra... conventional su... radiation thera... | - 65 Years | National Cancer Institute (NCI) | |
| Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00875615 | Liver Cancer | Carboplatin Cisplatin Sorafenib | 18 Years - 120 Years | University of Miami | |
| Chemotherapy in Treating Patients With Liver Cancer | NCT00003044 | Liver Cancer | cisplatin-e the... | 18 Years - | National Cancer Institute (NCI) | |
| Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer | NCT00607828 | Liver Cancer | stereotactic bo... | 19 Years - 120 Years | University of Nebraska | |
| Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis | NCT01079767 | Liver Cancer | temsirolimus | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| IMC-A12 in Treating Patients With Advanced Liver Cancer | NCT00639509 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cixutumumab computed tomogr... contrast-enhanc... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | NCT00486356 | Extrahepatic Bi... Gallbladder Can... Gastric Cancer Liver Cancer Unspecified Adu... | capecitabine carboplatin epirubicin hydr... microarray anal... polymorphism an... pharmacological... | 18 Years - 120 Years | University of Nebraska | |
| Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | NCT01624285 | Adult Primary H... Localized Resec... Localized Unres... Recurrent Adult... | sorafenib tosyl... placebo laboratory biom... | 19 Years - | Jonsson Comprehensive Cancer Center | |
| Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | NCT00071994 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | NCT00047346 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | erlotinib hydro... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | NCT00093444 | Liver Cancer Metastatic Canc... | lyso-thermosens... radiofrequency ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | NCT00023946 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Extra... Localized Gallb... Localized Resec... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | ixabepilone laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | NCT00087191 | Advanced Adult ... Carcinoma of th... Fallopian Tube ... Gastrointestina... Localized Extra... Localized Gallb... Localized Gastr... Localized Resec... Localized Unres... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Primary Periton... Recurrent Adult... Recurrent Adult... Recurrent Colon... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Small... Recurrent Uteri... Regional Gastro... Small Intestine... Small Intestine... Small Intestine... Stage 0 Non-sma... Stage I Adult S... Stage I Colon C... Stage I Gastric... Stage I Non-sma... Stage I Ovarian... Stage I Ovarian... Stage I Pancrea... Stage I Rectal ... Stage I Uterine... Stage II Adult ... Stage II Colon ... Stage II Gastri... Stage II Non-sm... Stage II Ovaria... Stage II Ovaria... Stage II Pancre... Stage II Rectal... Stage II Uterin... Stage III Adult... Stage III Colon... Stage III Gastr... Stage III Ovari... Stage III Ovari... Stage III Pancr... Stage III Recta... Stage III Uteri... Stage IIIA Non-... Stage IIIB Non-... Stage IV Adult ... Stage IV Colon ... Stage IV Gastri... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Stage IV Uterin... Unresectable Ex... Unresectable Ga... | EF5 motexafin lutet... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer | NCT00009893 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | fluorouracil gemcitabine hyd... leucovorin calc... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00335829 | Liver Cancer | bevacizumab chemotherapy embolization th... hepatic artery ... | 18 Years - 120 Years | Yale University | |
| Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | NCT00006016 | Adult Primary H... Advanced Adult ... Localized Unres... | thalidomide doxorubicin hyd... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed | NCT00006006 | Liver Cancer | recombinant int... thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00867321 | Liver Cancer | bevacizumab sorafenib tosyl... | 18 Years - 120 Years | Alliance for Clinical Trials in Oncology | |
| Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | NCT00844168 | Adult Primary H... Advanced Adult ... Localized Resec... Localized Unres... Recurrent Adult... | sorafenib tosyl... laboratory biom... | 18 Years - | University of Washington | |
| Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | NCT00033462 | Adult Primary C... Adult Primary H... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00238394 | Adult Primary H... Advanced Adult ... Localized Unres... | cediranib malea... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00514228 | Liver Cancer | sunitinib malat... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| 3-Tesla MRI Response to TACE in HCC (Liver Cancer) | NCT02057874 | Adult Primary H... Advanced Adult ... Localized Resec... Localized Unres... Stage A Adult P... Stage B Adult P... | 3 Tesla Magneti... Magnevist® (Int... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma | NCT00057980 | Liver Cancer | celecoxib epirubicin hydr... | 18 Years - | Northwestern University | |
| Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer | NCT00073905 | Extrahepatic Bi... Gallbladder Can... Liver Cancer Pain | capecitabine pl... | 18 Years - 80 Years | Swiss Group for Clinical Cancer Research | |
| AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | NCT00427973 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cediranib malea... laboratory biom... computed tomogr... dynamic contras... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | NCT00019474 | Extrahepatic Bi... Gastric Cancer Gastrointestina... Liver Cancer Pancreatic Canc... Small Intestine... | filgrastim recombinant int... fluorouracil hydroxyurea | 18 Years - 120 Years | Montefiore Medical Center | |
| Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery | NCT00049322 | Liver Cancer | bevacizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Irinotecan and Capecitabine in Treating Patients With Solid Tumors | NCT00003867 | Cancer | capecitabine irinotecan hydr... | 18 Years - 120 Years | Montefiore Medical Center | |
| Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer | NCT00257426 | Liver Cancer | octreotide acet... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00589030 | Liver Cancer | brachytherapy yttrium Y 90 gl... | 18 Years - | City of Hope Medical Center | |
| Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery | NCT00109954 | Liver Cancer | cisplatin brachytherapy yttrium Y 90 gl... | 18 Years - 120 Years | University of Pittsburgh | |
| Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer | NCT00003296 | Extrahepatic Bi... Gallbladder Can... Liver Cancer | filgrastim pegylated lipos... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | NCT00276705 | Liver Cancer | cisplatin cyclophosphamid... doxorubicin hyd... thalidomide adjuvant therap... conventional su... neoadjuvant the... | - 29 Years | National Cancer Institute (NCI) | |
| Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen | NCT00016380 | Cancer | dexamethasone ondansetron quality-of-life... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery | NCT01497444 | Kidney Cancer Liver Cancer | hypoxia-activat... sorafenib tosyl... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis | NCT01079767 | Liver Cancer | temsirolimus | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00589030 | Liver Cancer | brachytherapy yttrium Y 90 gl... | 18 Years - | City of Hope Medical Center | |
| Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery | NCT00049322 | Liver Cancer | bevacizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | NCT00293397 | Liver Cancer | Drug-eluting be... | 18 Years - 120 Years | Yale University | |
| Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery | NCT01859182 | Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Localized Unres... Metastatic Extr... Recurrent Adult... Recurrent Extra... Stage II Gallbl... Stage IIIA Gall... Stage IIIB Gall... Stage IVA Gallb... Stage IVB Gallb... Unresectable Ex... | selumetinib Akt inhibitor M... laboratory biom... pharmacogenomic... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery | NCT00471484 | Liver Cancer | recombinant int... doxorubicin hyd... fluorouracil oxaliplatin diagnostic labo... immunoenzyme te... immunohistochem... adjuvant therap... biopsy neoadjuvant the... therapeutic con... | 16 Years - 75 Years | National Cancer Institute (NCI) | |
| Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT00524316 | Liver Cancer | doxorubicin hyd... sunitinib malat... laboratory biom... hepatic artery ... quality-of-life... | 18 Years - 120 Years | Roswell Park Cancer Institute | |
| Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | NCT00101036 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer | NCT00483405 | Liver Cancer | cetuximab capecitabine oxaliplatin | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
